ATX
data caveat$56M24mo
Amplia Therapeutics
Biotech · Oncology
FAK inhibitor AMP945 for pancreatic and ovarian cancer
Data HealthTrials2 of 2 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$27.9M
Mar 2026 4C
Runway
24moSTABLE
Based on Mar 2026 4C
Market Cap
$56M
Burn Rate
$3.5M/qtr
Mar 2026 4C
Shares Outstanding
513M
Pipeline Assets
1
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther18 May 2026
Amplia Launches First Stage of Pivotal Narmafotinib Trial
Amplia Therapeutics is launching a Phase 2b registration-enabling trial of narmafotinib in advanced pancreatic cancer, investigating a new daily dosing regimen in combination with gemcitabine and Abraxane. The study, designed with FDA feedback, will enroll 12 patients across 3-4 Australian sites beginning Q4 2026, with safety and efficacy readout expected Q2 2027, forming the first stage of a registrational submission.
3M Price
ATX.ASX$0.110-4.3% 3M
Low $0.110High $0.265
Pipeline Assets (1)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
3 transactionsLast 90dNet Buy
Buys1+1 vs prior
Sells0
2026-03-30
32d before · PHASE1/PHASE2 data readout — ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment
Catalysts (5)· 4 upcoming · 1 past
SpeculativeremoveMed1 May 2026
ExpectedMed
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· 1 catalyst re-guided (2×)· of 5 tracked
Filed 1 of 1 4Cs on time· statutory deadline
What drove these scores · rolling 2yr
arrow_drop_down
PHASE1/PHASE2 data readout — A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patient — Upcoming — delayed 2× from original date
Completed catalysts
✓Amplia and ANZGOG announce Ovarian Cancer Study— Amplia Therapeutics and ANZGOG have entered into an agreement to conduct the PRROSE trial, evaluating narmafotinib (FAK inhibitor) combined with standard-of-care chemotherapy in high-grade serous ovarian cancer patients with poor response to initial platinum-based chemotherapy. The study will enrol approximately 15-20 patients and assess safety and potential to improve surgical outcomes in an indication with significant unmet medical need.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
2 activeClinicalTrials.gov ↗
Ph1/PHASE2Active Not RecruitingEnrollment stale · 296d
narmafotinib ascending dosesnarmafotinib dose comparison
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer Metastatic
18 Years+
Primary endpoint Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study
ENROL67
no manual snapshots — enter via record_enrollment.py
Ph1/PHASE2Active Not RecruitingEnrollment stale · 1471d
AMP945 ascending dosesAMP945 RP2D
ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Pancreatic Cancer · PDAC · Pancreatic Ductal Adenocarcinoma
18 Years+
Primary endpoint Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study
ENROL62
no manual snapshots — enter via record_enrollment.py
Announcements(20)
description
Annual ReportPS
Preliminary Final Report and Annual Report YE 31 March 202629 May 2026
12364KB
article
OtherPSauto_awesome
Amplia Launches First Stage of Pivotal Narmafotinib Trial18 May 2026
expand_more120KB